Xenoantigen, an αGal epitope-expression construct driven by the hTERT-promoter, specifically kills human pancreatic cancer cell line

Cancer Cell International

Volumn 2, Issue , 2002, Pages

  Sawada, Tokihiko ^a   Yamada, Osamu ^a   Yoshimura, Naoko ^a   Hatori, Keiko ^a   Fuchinoue, Shohei ^a   Teraoka, Satoshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ANTIBODY; EPITOPE; LECTIN; LIPOCORTIN 5; TELOMERASE REVERSE TRANSCRIPTASE; VIRUS VECTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL KILLING; CELL SURFACE; COMPLEMENT DEPENDENT CYTOTOXICITY; EXPRESSION VECTOR; FLOW CYTOMETRY; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PANCREAS CANCER; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIMIAN VIRUS 40;

EID: 0242538317     PISSN: 14752867     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2867-2-14     Document Type: Article

References (23)

1. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S: A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 2000, 11:1397-1406
2. Majumdar AS, Hughes DE, Lichsteiner SP, Wang Z, Lebkowski JS, Vasserot AP: The telomerase reverse transcriptase promoter drives efficious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene therapy 2001, 8:568-578
3. Feng J, Funk WD, Wang S-S, Weinrich SL, Avilion AA, Chiu C-P, Adams RR, Greider CW, Villeponteau B: The RNA component of human telomerase. Science 1995, 269:1236-1241
4. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Linger J, Harley CB, Cech TR: Telomerase catalytic subunit homologs from fishion yeast and human. Science 1997, 277:955-959
5. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay J: Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996, 18:173-179
6. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015
7. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S, Greider CW: Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 1996, 56:643-659
8. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33:787-791
9. Kilian A, Bowtell DDL, Abud HE, Hime GR, Venter DJ, Keese PK, Dunkan EL, Reddel RR, Jefferson RA: Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 1997, 6:2011-2019
10. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M: Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification between of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999, 59:551-557
11. Wick M, Zubov D, Hagen G: Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 1999, 232:97-106
12. Gallili U: Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 1993, 14:480-482
13. Dalmasso AP, Vercellotti GM, Fischel RJ, Bolman RM, Bach FH, Platt JL: Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992, 140:1157-1166
14. Joziasse DH, Shaper NL, Kim D, Van den Eijinden DH, Shaper JH: Murine α 1, 3-galactosyltransferase. J Biol Chem 1992, 267:5534-5541
15. Yoshimura N, Sawada T, Furusawa M, Fuchinoue S: Expression of xenoantigen transformed human cancer cells to be susceptible to antibody-mediated cell killing. Canc Letters 2001, 164:155-160
16. Rus H, Niculescu F: The complement system in central nervous system diseases. Immunol Res 2001, 24:79-86
17. Oelschlaegel U, Besson I, Arnoulet C, Sainty D, Nowak R, Naumann R, Bux Y, Ehninger G: A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes. Clin Lab Haematol 2001, 23:81-90
18. Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Ohashi R, Sugisaki Y, Yamanaka N: Complement-mediated killing of mesangial cells in experimental glomerulonephritis: cell death by a combination of apoptosis and necrosis. Nephron 2000, 86:152-160
19. Akiyama M, Iwase S, Horiguchi-Yamada J, Saito S, Furukawa Y, Yamada O, Mizoguchi H, Ohno T, Yamada H: Interferon-α repressed telomerase along with G1-accumulation of Daudi cells. Canc Letters 1999, 142:23-30
20. Larsen RD, Rivera-Marrero CA, Ernst LK, Cummings RD, Lowe JB: Frameshift and nonsense mutations in a human genomic sequence homologues to a murine UDP-Gal: β-D-Gal(1, 4)-DGlcNAcα(1,3 -galactosyltransferase cDNA. J Biol Chem 1990, 265:7055-7061
21. Yunis AA, Arimura GK, Russin DJ: Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 1977, 19:128-135
22. Nakabayashi K, Ogata T, Fujii M, Tahara H, Ide T, Wadhwa R, Kaul SC, Mitsui Y, Ayusawa D: Decrease in amplified telomeric sequence and induction of senescence markers by introduction of human chromosome 7 or its segments in SUSM-1. Exp Cell Res 1997, 235:345-353
23. Wood C, Kabat EA, Murphy LA, Goldstein IJ: Immunochemical studies of the combining sites of the two isolectins, A4 and B4 isolated from Bandeiraea simplicifolia. Arch Biochem Biophys 1979, 198:1-11